×

Business / Stock Market

AstraZeneca : Enhertu Shows Robust And Durable Tumor Response Of 54. 9% In Patients With Lung Cancer

Published Sep 18 2021 at 1:54 PM GMT

Business Insider

Business Insider @businessinsider.com

Add to Collections
Report Post

Continue reading at businessinsider.com

Key
Points

L) and Daiichi Sankyo's HER2-directed antibody drug conjugate, Enhertu, demonstrated robust and durable tumor response of 54.9% in previously treated patients with HER2-mutant or HER2m unresectable and/or metastatic non-squamous non-small cell lung cancer or NSCLC.
Data from HER2-mutant cohort of pivotal.

Credit

Tags

Continue reading at businessinsider.com

Posted in Business, Stock Market

Stats

Published Sep 18, 2021 1:54 PM GMT